2 September 2010 in BMC Cancer
Human neuroblastoma (NB) cell lines may present with either one of the so-called S-and N-subtypes. We have previously reported a strong correlation between protein expression levels of vimentin, an S-subtype marker, and the p21Waf1 cyclin-dependent kinase inhibitor. We here investigated whether this correlation extend to the mRNA level in NB cell lines as well as in patients' tumors. We also further explored the relationship between expression of vimentin and p21, by asking whether vimentin could regulate p21 expression. Vimentin and p21 mRNA levels in NB cell lines as well as in patients' tumors (n = 77) were quantified using Q-PCR. Q-PCR data obtained from tumors of high risk NB patients (n = 40) were analyzed in relation with the overall survival using the Log-rank Kaplan-Meier estimation. siRNA-mediated depletion or overexpression of vimentin in highly or low expressing vimentin cell lines, respectively, followed by protein expression and promoter activation assays were used to assess the role of vimentin in modulating p21 expression. We extend the significant correlation between vimentin and p21 expression to the mRNA level in NB cell lines as well as in patients' tumors. Overall survival analysis from Q-PCR data obtained from tumors of high risk patients suggests that lower levels of p21 expression could be associated with a poorer outcome. Our data additionally indicate that the correlation observed between p21 and vimentin expression levels results from p21 transcriptional activity being regulated by vimentin. Indeed, downregulating vimentin resulted in a significant decrease in p21 mRNA and protein expression as well as in p21 promoter activity. Conversely, overexpressing vimentin triggered an increase in p21 promoter activity in cells with a nuclear expression of vimentin. Our results suggest that p21 mRNA tumor expression level could represent a refined prognostic factor for high risk NB patients. Our data also show that vimentin regulates p21 transcription; this is the first demonstration of a gene regulating function for this type III-intermediate filament.
1 June 2008 in Archives de Pédiatrie
1 December 2007 in Oncologie
La majorité des maladies malignes de l’enfant sont curables grâce à des chimiothérapies conventionnelles. Cependant, la greffe de cellules souches hématopoïétiques autologues permet d’intensifier la chimiothérapie et de guérir des maladies chimiosensibles non curables par les traitements conventionnels et garde une place à part entière dans les stratégies pédiatriques. C’est le cas pour les neuroblastomes de haut risque et les tumeurs d’Ewing métastatiques. Dans les tumeurs cérébrales, la place de la chimiothérapie à hautes doses unique ou séquentielle avec un soutien par autogreffe est en cours d’évaluation. L’objectif est alors non seulement d’améliorer la survie des patients, mais aussi leur pronostic fonctionnel. En outre, sont développés des traitements d’entretien postgreffe chimiothérapiques ou non visant à améliorer le contrôle de la maladie résiduelle minime persistant après greffe. Most paediatric malignancies can be cured with conventional chemotherapy. Autologous stem cell transplantation makes it possible to dramatically increase chemotherapy doses and cure tumours that were resistant to conventional chemotherapy, such as high-risk neuroblastoma and metastatic Ewing sarcoma. High-dose chemotherapy and autologous transplantation are major tools in treating patients who have very high-risk malignancies. In patients with brain tumours, it aims at improving prognosis and decreasing sequelae. Maintenance therapy has been developed to follow high-dose chemotherapy and treat minimal, persistent, residual disease.